within Pharmacolibrary.Drugs.ATC.J;

model J01CE10
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 0.21666666666666667,
    adminDuration  = 600,
    adminMass      = 1.2,
    adminCount     = 1,
    Vd             = 0.015,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 5e-05,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Benzathine phenoxymethylpenicillin is a long-acting penicillin antibiotic, consisting of phenoxymethylpenicillin (penicillin V) in combination with benzathine to provide an extended-release intramuscular formulation. It was used for prophylaxis and treatment of infections caused by penicillin-sensitive microorganisms, particularly in streptococcal infections, but is not widely marketed or clinically used today.</p><h4>Pharmacokinetics</h4><p>No peer-reviewed pharmacokinetic data for benzathine phenoxymethylpenicillin in humans available. The following represents a theoretical estimate for adults after intramuscular administration (extrapolated from similar benzathine penicillin G and phenoxymethylpenicillin profiles).</p><h4>References</h4><ol><li><p>Belov, BS, et al., &amp; Makarova, RA (2000). [A comparative evaluation of the pharmacokinetics of different forms of benzathine benzylpenicillin]. <i>Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic]</i> 45(4) 18â€“21. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/10851645/&quot;>https://pubmed.ncbi.nlm.nih.gov/10851645</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end J01CE10;
